New drug combo before surgery for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-positive breast cancer (confirmed by a lab test).
- Your tumor must be larger than 2 centimeters and have not spread to other parts of the body.
- You cannot have had any previous treatment for breast cancer (like chemotherapy or targeted therapy).
- You must be healthy enough to have surgery after the study treatment.
- You must have good heart, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.